Clinical trials: Idarubicin
Leukemia, Myeloid, Acute
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior induction regimens: Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion…
- Trial name
- NCT03926624
- Testing
- DFP-10917, Cytarabine, Azacitidine
- Where
- 39 sites in United States
- Volunteers
- 167 people
- Sponsor
- Delta-Fly Pharma, Inc.
Leukemia, Myeloid, Acute
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of bleximenib in combination with AML directed therapies (dose selection) and further to evaluate safety and tolerability of bleximenib in…
- Trial name
- NCT05453903
- Testing
- Bleximenib, Venetoclax (VEN), Azacitidine (AZA)
- Where
- 32 sites in United States, Australia and 6 more
- Volunteers
- 196 people
- Sponsor
- Janssen Research & Development, LLC
Acute Myeloid Leukemia
Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)
The goal of this clinical trial is to compare the clinical efficacy and safety of IAC regimen and IA regimen as induction chemotherapy for initial diagnosed acute myeloid leukemia (AML) patients.
- Trial name
- NCT02323022
- Testing
- IAC regimen, IA regimen
- Where
- China
- Volunteers
- 618 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia
Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study
This is a multicenter, single-arm, open-label clinical study designed to evaluate the efficacy and safety of an integrated "induction-consolidation-transplantation" treatment protocol in adult patients with acute myeloid leukemia…
- Trial name
- NCT07108530
- Testing
- Integrated IAV/MA Chemotherapy and Allo-HSCT Protocol for Adult AML, First Induction (IAV or DAV Regimen), Consolidation Therapy Options: MA or Intermediate-Dose Cytarabine Regimen
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanxi Bethune Hospital
Leukemia
Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as mitoxantrone hydrochloride, cytarabine, etoposide, and idarubicin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from…
- Trial name
- AML1208 (NCT01154439)
- Testing
- cytarabine, etoposide, everolimus
- Where
- 5 sites in Italy
- Volunteers
- 11 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Lymphoma, Non-Hodgkin
A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
The purpose of this study is to confirm that the pharmacokinetics of ibrutinib in pediatric participants is consistent with that in adults (part 1) and to assess efficacy (event-free survival [EFS]) of ibrutinib in combination…
- Trial name
- NCT02703272
- Testing
- Ibrutinib, Rituximab, Ifosfamide
- Where
- 76 sites in United States, Belgium and 18 more
- Volunteers
- 72 people
- Sponsor
- Janssen Research & Development, LLC
Acute Lymphoblastic Leukemia
Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS
Trial protocol intended the optimization of induction treatment with: 1. Inclusion of PEG-ASP in induction and in the three blocks of consolidation. 2.
- Trial name
- NCT01540812
- Testing
- Vincristine in induction, Daunorubicin in induction, Prednisone in induction
- Where
- Spain
- Volunteers
- 418 people
- Sponsor
- PETHEMA Foundation
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a)
Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS
The goals of this study are to learn about the effectiveness, the side-effects, if waiting to give the idarubicin and cytarabine may change the side effects or effectiveness, and to identify factors to predict for responses to…
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2)
- Trial name
- NCT01607645
- Testing
- decitabine, idarubicin, cytarabine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Fred Hutchinson Cancer Center
Newly Diagnosed Acute Myeloid Leukemia (AML), Elderly Patients
Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia
This study is a multicenter, prospective, randomized, controlled clinical trial, observing the efficacy and safety of the CACAG+Venetoclax regimen (Chidamide + Azacitidine + Aclarubicin + Cytarabine + Recombinant Human…
- Trial name
- NCT07514936
- Testing
- the standard "3+7" regimen, Azacytidine; Cytarabine; Aclacinomycin; Chidamide; Venetoclax; Granulocyte
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Chinese PLA General Hospital
Non-hodgkin Lymphoma,B Cell, Burkitt Lymphoma
B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021
The aim of the trial is to evaluate the molecular characteristics and MDD/MRD of B-NHL in pediatric patients in order to identify on the one hand the very high risk group and to prescribe them more intensive treatment on the…
- Conditions
- Non-hodgkin Lymphoma,B Cell, Burkitt Lymphoma, Primary Mediastinal Lymphoma, Primary CNS Lymphoma
- Trial name
- NCT05518383
- Testing
- Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine
- Where
- Russia
- Volunteers
- 300 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Acute Myeloid Leukemia
Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML
This study evaluates the efficacy and safety of the combination of idarubicin and cytarabine induction followed by intermediate-dose cytarabine consolidation with venetoclax in the treatment of newly diagnosed adult acute myeloid…
- Trial name
- NCT06232694
- Testing
- Venetoclax : 100mg on day 1, 200mg on day 2, 400mg on days 3 to 8; oral administration;, Venetoclax (Venetoclax): 400mg on day 1 to day 7; oral administration;, utologous stem cell transplantation (ASCT) /allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Where
- China
- Volunteers
- 54 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Acute Myeloid Leukemia
Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML
The purpose of this study is to evaluate whether HLA-mismatched donor G-CSF mobilized peripheral blood mononuclear cell (GPBMC) infusion with venetoclax-containing regimens (microtransplant, MST) could improve survival in adult…
- Trial name
- NCT07078591
- Testing
- Venetoclax, Azacitidine (AZA), Daunorubicin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Beijing 302 Hospital
Autologous Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia
IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCT
Autologous hematopoietic stem cell transplantation (Auto-HSCT) is an effective alternative to allogeneic HSCT for intermediate-risk acute myeloid leukemia (AML) without HLA-matched donors.
- Conditions
- Autologous Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia, Conditioning
- Trial name
- NCT02671708
- Testing
- Idarubicin（IDA）, Busulfan (BU), Cyclophosphamide (CY)
- Where
- China
- Volunteers
- 153 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Acute Myeloid Leukemia
Treatment of Acute Myeloid Leukemia (AML) in Adults 50 to 70 Years, Study of Two Anthracyclines and the Interest of Maintenance Treatment With Interleukin 2
Randomized comparison of standard induction treatment with daunorubicin for 3 days and Idarubicin for 3 or 4 days in adult AML patients between 50 and 70 years. Study of maintenance treatment with IL2
- Trial name
- ALFA 9801 (NCT00931138)
- Testing
- chemotherapy (Aracytine + Daunorubicin)
- Where
- 16 sites in France
- Volunteers
- 420 people
- Sponsor
- Acute Leukemia French Association
Leukemia, Myelodysplastic Syndromes
Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Trial name
- NCT00002926
- Testing
- cytarabine, etoposide, idarubicin
- Where
- 40 sites in Belgium, Croatia and 7 more
- Volunteers
- 80 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
This phase III trial studies tretinoin and arsenic trioxide in treating patients with newly diagnosed acute promyelocytic leukemia.
- Trial name
- NCT02339740
- Testing
- Arsenic Trioxide, Cytarabine, Dexamethasone
- Where
- 174 sites in United States, Australia and 4 more
- Volunteers
- 158 people
- Sponsor
- Children's Oncology Group
Acute Myeloid Leukemia
Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML
The orally administered second-generation bis-aryl urea tyrosine kinase inhibitor quizartinib is very specific for FLT3, has a high capacity for sustained FLT3-inhibition and an acceptable toxicity profile.
- Trial name
- Q-SOC (NCT04676243)
- Testing
- Quizartinib, Treatment according to Physician's Choice, Standard of Care Chemotherapy
- Sponsor
- University Hospital Heidelberg
Acute Myeloid Leukemia
the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient
This study was a multi-center, open, randomized-control study on the effects and safety of idarubicin 60mg/M2 combined with BUCY pretreatment program or BUCY pretreatment program on the overall survival rate and disease-free…
- Trial name
- IDBUCY (NCT01766375)
- Testing
- Cyclosporin A,mycophenolate mofetil,Methotrexate
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Guangxi Medical University
Acute Myeloid Leukemia
Adding Lomustine to Chemotherapy in Older Patients With Acute Myelogenous Leukemia (AML), and Allogeneic Transplantation for Patients From 60 to 65 Years Old
A multicenter randomized trial comparing induction therapy (IC: Idarubicin and Cytarabine, 5 + 7) to ICL (the same drugs plus lomustine (CCNU), 200 mg/m2 orally at day 1).
- Trial name
- LAM-SA 2007 (NCT00590837)
- Testing
- Lomustine
- Where
- 32 sites in France
- Volunteers
- 459 people
- Sponsor
- University Hospital, Bordeaux
Nucleophosmin 1-mutated Acute Myeloid Leukemia
Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML
The primary objective of this study is to evaluate the efficacy of entospletinib (ENTO) compared to placebo when added to chemotherapy in previously untreated nucleophosmin-1 mutated (NPM1-m) acute myeloid leukemia (AML), as…
- Trial name
- NCT05020665
- Testing
- Entospletinib, Cytarabine, Anthracycline
- Where
- 83 sites in United States, Brazil and 10 more
- Volunteers
- 15 people
- Sponsor
- Kronos Bio